首页> 美国卫生研究院文献>Oncotarget >Cryoablation combined with allogenic natural killer cell immunotherapy improves the curative effect in patients with advanced hepatocellular cancer
【2h】

Cryoablation combined with allogenic natural killer cell immunotherapy improves the curative effect in patients with advanced hepatocellular cancer

机译:冷冻消融联合同种异体自然杀伤细胞免疫疗法可提高晚期肝细胞癌患者的疗效

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In this study, the clinical efficacy of cryosurgery combined with allogenic natural killer cell immunotherapy for advanced hepatocellular cancer was evaluated. From October 2015 to March 2017, we enrolled 61 patients who met the enrollment criteria and divided them into two groups: 1) the simple cryoablation group (Cryo group, n = 26); and 2) the cryoablation combined with allogenic natural killer cells group (Cryo-NK group, n = 35), the safety and short-term effects were evaluated firstly, then the median progression-free survival, response rate and disease control rate were assessed. All adverse events experienced by the patients were recorded, and included local (e.g., pain, pleural effusion, and ascites) and systemic (e.g., chills, fatigue, and fever) reactions, fever was more frequent. Other possible seriously side effects (e.g., blood or bone marrow changes) were not detected. Combining allogeneic natural killer cells with cryoablation had a synergistic effect, not only enhancing the immune function, improving the quality of life of the patients, but also reducing the expression of AFP and significantly exhibiting good clinical efficacy of the patients. After a median follow-up of 8.7 months (3.9 –15.1months), median progression-free survival was higher in Cryo-NK (9.1 months) than in Cryo (7.6 months, P = 0.0107), median progression-free survival who received multiple natural killer was higher than who just received single natural killer (9.7 months vs.8.4 months, P = 0.0011, respectively), the response rate in Cryo-NK (60.0%) was higher than in Cryo (46.1%, P < 0.05), the disease control rate in Cryo-NK (85.7%) was higher than in Cryo group (69.2%, P < 0.01). Percutaneous cryoablation combined with allogeneic natural killer cell immunotherapy significantly increased median progression-free survival of advanced hepatocellular cancer patients. Multiple allogeneic natural killer cells infusion was associated with better prognosis to advanced hepatocellular cancer.
机译:在这项研究中,评估了冷冻疗法联合同种异体自然杀伤细胞免疫疗法治疗晚期肝细胞癌的临床疗效。从2015年10月至2017年3月,我们纳入了符合入组标准的61位患者,并将其分为两组:1)简单冷冻消融组(Cryo组,n = 26); 2)冷冻消融联合同种异体自然杀伤细胞组(Cryo-NK组,n = 35),首先评估其安全性和短期效果,然后评估中位无进展生存期,缓解率和疾病控制率。记录患者经历的所有不良事件,包括局部(例如疼痛,胸腔积液和腹水)和全身性(例如发冷,疲倦和发烧)反应,发烧更加频繁。未检测到其他可能的严重副作用(例如血液或骨髓变化)。将同种异体自然杀伤细胞与冷冻消融相结合具有协同作用,不仅增强了免疫功能,改善了患者的生活质量,而且降低了AFP的表达,显着展现了良好的临床疗效。在中位随访8.7个月(3.9 – 15.1个月)后,接受Cryo-NK的中位无进展生存(9.1个月)高于接受Cryo的中位无进展生存(7.6个月,P = 0.0107)。多重自​​然杀手的发生率高于接受单一自然杀手的人(分别为9.7个月和8.4个月,P = 0.0011),Cryo-NK的应答率(60.0%)高于Cryo-NK(46.1%,P <0.05) ),Cryo-NK的疾病控制率(85.7%)高于Cryo组(69.2%,P <0.01)。经皮冷冻消融结合同种异体自然杀伤细胞免疫疗法可显着提高晚期肝细胞癌患者的中位无进展生存期。多次同种异体自然杀伤细胞输注与晚期肝细胞癌的更好预后相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号